Product
ADX-629
7 clinical trials
7 indications
Indication
nephrotic syndromeIndication
Alcohol IntoxicationIndication
PsoriasisIndication
AsthmaIndication
COVID-19Indication
Chronic CoughIndication
Sjogren-Larsson SyndromeClinical trial
A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects With Frequently Relapsing and Steroid-Dependent Nephrotic SyndromeStatus: Withdrawn, Estimated PCD: 2023-05-01
Clinical trial
A Double-Blind Clinical Trial to Assess the Interaction Between ADX-629 and Ethanol While Exploring the Safety, Tolerability, and Activity of ADX-629 in Subjects With Elevated Ethanol LevelsStatus: Completed, Estimated PCD: 2022-05-29
Clinical trial
A Multi-Center, Open-Label, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects With Plaque PsoriasisStatus: Completed, Estimated PCD: 2022-01-21
Clinical trial
A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of ADX-629 in Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)Status: Completed, Estimated PCD: 2022-01-18
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics of ADX-629 Administered Orally for the Treatment of COVID-19Status: Completed, Estimated PCD: 2021-10-15
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects With Chronic CoughStatus: Completed, Estimated PCD: 2023-04-13
Clinical trial
An Open-Label, Phase 1/2, Single-Site Study of the Safety, Biochemical Efficacy, and Exploratory Clinical Effects of Oral ADX-629 in Subjects With Sjögren-Larsson SyndromeStatus: Recruiting, Estimated PCD: 2025-06-30